Study Title and Description
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Key Questions Addressed
|2||KQ2a. What is the comparative effectiveness of nonopioid pharmacologic therapy (e.g. acetaminophen, NSAIDs, triptans, ergots alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) other nonopioid pharmacologic treatments, such as those in a different medication class; or 2) nonpharmacologic therapy for outcomes related to pain, function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? KQ2b. How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics (e.g. age, race, ethnicity, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication; (4) dose of medication; (5) duration of treatment? KQ2c. What are the harms of nonopioid pharmacologic therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1) misuse, (2) overdose; (3) MOH, (4) other harms including gastrointestinal-related harms, cardiovascular-related harms, kidney-related harms, falls, fractures, motor vehicle accidents, endocrinological harms, infections, cognitive harms, and psychological harms (e.g. depression)? KQ2d. How do harms vary depending on: (1) patient demographics (e.g. age, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication; (4) dose of medication; (5) the duration of therapy?|
Primary Publication Information
|Title||Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.|
|Author||Croop R., Goadsby PJ., Stock DA., Conway CM., Forshaw M., Stock EG., Coric V., Lipton RB.|
|Country||Biohaven Pharmaceuticals, New Haven, CT, USA. Electronic address: firstname.lastname@example.org.|
Pubmed ID: 31311674
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Question 2
|Question... Follow Up||Answer||Follow-up Answer|
Results & Comparisons
No Results found.